Finance

Pharmalot

Pharmalittle: Opioid trial underway as distributors try to settle; patients beg DEA to reconsider opioid production cuts

By Ed Silverman

Lots of people
Biotech

How Colorado firefighters, a Hawaiian charity, and TV writers are fueling the biotech boom

By Kate Sheridan

colored DNA sequencing
Business

Illumina confronts the innovator’s dilemma

By Matthew Herper

Changzhou Qianhong Biochemical
First Opinion

As tariffs affect the pharma industry, business strategies must evolve

By Roddy Martin

First Opinion

Trump’s trade war is hurting companies like mine — and the biotechnology industry

By Mahesh Narayanan

Pharmalot
Pharmalot

Catalyst stock dives, although the fledgling drug maker has no idea why

By Ed Silverman

biotech invest
Biotech

RA Capital launches Carnot, an incubator for early-stage biotechs

By Kate Sheridan

Ginkgo Bioworks 06
Biotech

Ginkgo Bioworks scores an eye-popping valuation with latest fundraise

By Jonathan Saltzman — Boston Globe

Christopher Reeve and his wife Dana
Business

Reeve Foundation to invest in paralysis-treatment companies, as more nonprofits act like VCs

By Rebecca Robbins

Pharmalot

Pharmalittle: Purdue bankruptcy sets tone for opioid cases; Sanders criticizes Biden for praising pharma

By Ed Silverman

Financial toxicity
First Opinion

Ease financial toxicity by putting electronic medical records to work

By Walter J. O’Donnell

Purdue Pharma headquarters
Business

Purdue Pharma, maker of OxyContin and other drugs, files for bankruptcy

By Andrew Joseph

Pharmalot

Pharmalittle: Mallinckrodt mulls restructuring as opioid trial nears; the next FDA commissioner will be …

By Ed Silverman

Biohacking conference logo
Biotech

‘I propose that we grow up a little bit’: Biohackers grapple with when to reject mainstream science — and when to embrace it

By Rebecca Robbins

Pharmalot

Pharmalittle: Merck calls new Canadian pricing rules unconstitutional; J&J ruling today

By Ed Silverman

Pharmalot

Pharmalittle: Are Trump supporters less concerned with drug prices? An Amgen-Alexion report draws skepticism

By Ed Silverman

Something ventured illo
Something Ventured

Compass Therapeutics and these three other biotech startups got venture funding a year ago. Where are they now?

By Kate Sheridan

Pharmalot

Pharmalittle: Canada may ease price caps on rare disease drugs; lawmakers renew generic pricing probe

By Ed Silverman

Women supporting women
Health Tech

One health care startup at a time, this venture capitalist wants to harness the investing power of women

By Megan Thielking

Pharmalot

Pharmalittle: Canadians worried by Trump importation plan; pharma creates R&D hubs in China for data

By Ed Silverman

Pharmalot

Pharmalittle: Female CEOs in biotech are still rare; Arizona sues Sacklers in Supreme Court

By Ed Silverman

Briefcase full of money
Biotech

Life sciences VC firm Vida Ventures raises $600 million in second fund

By Kate Sheridan

Pharmalot

Pharmalittle: Amazon’s PillPack rival seeks help from FBI; a big payday for Mylan’s CEO

By Ed Silverman

Mylan
Pharmalot

For Mylan shareholders, the deal with Pfizer will ‘solve nothing’

By Ed Silverman

Pharmalot

Pharmalittle: Pfizer to merge off-patent business with Mylan; conservatives try to sabotage Trump pricing plan

By Ed Silverman

Charlie Baker
Pharmalot

Massachusetts lawmakers approve compromise bill to lower Medicaid drug spending

By Ed Silverman

Ear Hair Cells
Biotech

Frequency Therapeutics raises another $62 million

By Jonathan Saltzman — Boston Globe

Generic Drug Production - India
First Opinion

The Indian pharmaceutical industry is in denial over drug-quality charges

By Dinesh Thakur

Empty hospital bed
First Opinion

Economic barriers to organ transplants from living donors must be removed

By Yuri Genyk

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy